Eisai Acquires Four Oncology- Related Products From Ligand

Your AI-Trained Oncology Knowledge Connection!

Eisai Acquires Four Oncology- Related Products From Ligand

December 1, 2006

Publication

Article

Oncology NEWS InternationalOncology NEWS International Vol 15 No 12

Volume 15

Issue 12

Eisai Inc., the US subsidiary of Tokyo-based Eisai Co. Ltd., has completed acquisition of four oncology-related products from Ligand Pharmaceuticals: Ontak (denileukin diftitox), Targretin (bexarotene) capsules, Targretin (bexarotene) gel 1%, and Panretin (alitretinoin gel 0.1%. In other news, the company said it has begun work on a new oncology facility in Research Triangle Park, North Carolina.

TEANECK, New JerseyEisai Inc., the US subsidiary of Tokyo-based Eisai Co. Ltd., has completed acquisition of four oncology-related products from Ligand Pharmaceuticals: Ontak (denileukin diftitox), Targretin (bexarotene) capsules, Targretin (bexarotene) gel 1%, and Panretin (alitretinoin gel 0.1%. In other news, the company said it has begun work on a new oncology facility in Research Triangle Park, North Carolina.

Articles in this issue

Best Rx Most Cost-Effective: RTOG

Grape Seed Found to Be a Natural Aromatase Inhibitor

Drug Combination Prevents ER-Negative Tumors in Mice

Democrats' Agenda May Stifle Efforts for More Ca Funding

No Loss of Efficacy With Synchronous Chemotherapy/ESP

'Share Care' Difficult for Ca Survivors and Their Oncologists

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!

Eisai Acquires Four Oncology- Related Products From Ligand

Newsletter